CN1116283C - 作为细胞增殖抑制剂的氰基胍 - Google Patents

作为细胞增殖抑制剂的氰基胍 Download PDF

Info

Publication number
CN1116283C
CN1116283C CN98805595A CN98805595A CN1116283C CN 1116283 C CN1116283 C CN 1116283C CN 98805595 A CN98805595 A CN 98805595A CN 98805595 A CN98805595 A CN 98805595A CN 1116283 C CN1116283 C CN 1116283C
Authority
CN
China
Prior art keywords
compound
oxygen base
group
acid
cyano group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98805595A
Other languages
English (en)
Chinese (zh)
Other versions
CN1258279A (zh
Inventor
C·S·汉尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharmaceutical Products Ltd AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharmaceutical Products Ltd AS filed Critical Leo Pharmaceutical Products Ltd AS
Publication of CN1258279A publication Critical patent/CN1258279A/zh
Application granted granted Critical
Publication of CN1116283C publication Critical patent/CN1116283C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN98805595A 1997-05-29 1998-05-15 作为细胞增殖抑制剂的氰基胍 Expired - Lifetime CN1116283C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711125.6A GB9711125D0 (en) 1997-05-29 1997-05-29 Novel cyanoguanidines
GB9711125.6 1997-05-29

Publications (2)

Publication Number Publication Date
CN1258279A CN1258279A (zh) 2000-06-28
CN1116283C true CN1116283C (zh) 2003-07-30

Family

ID=10813255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98805595A Expired - Lifetime CN1116283C (zh) 1997-05-29 1998-05-15 作为细胞增殖抑制剂的氰基胍

Country Status (20)

Country Link
US (1) US6346541B1 (enExample)
EP (1) EP0984938B1 (enExample)
JP (1) JP4408455B2 (enExample)
KR (1) KR100496220B1 (enExample)
CN (1) CN1116283C (enExample)
AT (1) ATE249438T1 (enExample)
AU (1) AU733142B2 (enExample)
CA (1) CA2292895C (enExample)
CZ (1) CZ294842B6 (enExample)
DE (1) DE69818041T2 (enExample)
DK (1) DK0984938T3 (enExample)
ES (1) ES2206932T3 (enExample)
GB (1) GB9711125D0 (enExample)
HU (1) HUP0002921A3 (enExample)
NZ (1) NZ501071A (enExample)
PL (1) PL190314B1 (enExample)
PT (1) PT984938E (enExample)
RO (1) RO120541B1 (enExample)
RU (1) RU2195453C2 (enExample)
WO (1) WO1998054144A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US6255323B1 (en) 1999-04-09 2001-07-03 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU1494702A (en) 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
BR0209930A (pt) 2001-05-24 2004-03-30 Leo Pharma As Composto, composição farmacêutica, método para tratar doenças proliferativas, e, uso de um composto
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
PL228742B1 (pl) * 2002-05-17 2018-05-30 Leo Pharma As Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
EP1507759A1 (en) * 2002-05-17 2005-02-23 Leo Pharma A/S Cyanoguanidine produgs
WO2006037468A1 (en) * 2004-09-30 2006-04-13 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv reverse transcriptase inhibitors
CA2594508C (en) 2004-12-22 2013-10-01 Leo Pharma A/S Cyanoguanidine compounds
WO2006110298A2 (en) * 2005-03-25 2006-10-19 Glaxo Group Limited 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
CA2701071C (en) 2007-09-26 2018-03-27 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
WO2009086835A1 (en) * 2008-01-11 2009-07-16 Topotarget A/S Novel cyanoguanidines
MX2011002240A (es) 2008-08-29 2011-04-05 Topotarget As Nuevos derivados de urea y tiourea.
JP5580339B2 (ja) 2009-02-06 2014-08-27 ティエンジン ホーメイ バイオ−テック カンパニー， リミテッド ピリジルシアノグアニジンを含む薬物組成物、該組成物の製造方法及び応用
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
JP2013540781A (ja) 2010-10-26 2013-11-07 ティエンジン ホーメイ バイオ−テック カンパニー， リミテッド Ｎ−（６−（４−クロロフェノキシ）ヘキシル）−ｎ’−シアノ−ｎ’’−（４−ピリジル）グアニジンの結晶多形とその製造及び使用
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006770A1 (en) * 1992-09-15 1994-03-31 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) N-cyano-n'-pyridylguanidines as serotonin antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4530693A (en) * 1992-08-13 1994-03-15 Upjohn Company, The Cyanoguanidines as potassium channel blockers
ES2116726T3 (es) * 1994-01-28 1998-07-16 Upjohn Co Cianoguanidinas utilizadas como bloqueadores del canal k.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006770A1 (en) * 1992-09-15 1994-03-31 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) N-cyano-n'-pyridylguanidines as serotonin antagonists

Also Published As

Publication number Publication date
PL337030A1 (en) 2000-07-31
KR100496220B1 (ko) 2005-06-21
EP0984938B1 (en) 2003-09-10
CA2292895A1 (en) 1998-12-03
AU7638698A (en) 1998-12-30
JP4408455B2 (ja) 2010-02-03
EP0984938A1 (en) 2000-03-15
JP2001526694A (ja) 2001-12-18
HUP0002921A3 (en) 2002-10-28
CA2292895C (en) 2007-03-06
CZ294842B6 (cs) 2005-03-16
HUP0002921A2 (hu) 2001-01-29
ATE249438T1 (de) 2003-09-15
DK0984938T3 (da) 2004-01-12
NZ501071A (en) 2001-08-31
DE69818041T2 (de) 2004-07-08
GB9711125D0 (en) 1997-07-23
WO1998054144A1 (en) 1998-12-03
AU733142B2 (en) 2001-05-10
PT984938E (pt) 2004-02-27
RU2195453C2 (ru) 2002-12-27
PL190314B1 (pl) 2005-11-30
US6346541B1 (en) 2002-02-12
RO120541B1 (ro) 2006-03-30
ES2206932T3 (es) 2004-05-16
HK1027562A1 (en) 2001-01-19
DE69818041D1 (de) 2003-10-16
KR20010013148A (ko) 2001-02-26
CN1258279A (zh) 2000-06-28
CZ9904234A3 (cs) 2001-02-14

Similar Documents

Publication Publication Date Title
CN1116283C (zh) 作为细胞增殖抑制剂的氰基胍
CN1032750C (zh) 新的聚4-氨基-2-羟基-1-甲基化合物脲基衍生物的制备方法
CN1117081C (zh) 用芳基取代或杂芳基取代的杂环脲抑制raf激酶
CN1280266C (zh) 酰基苯基脲衍生物,其制备方法和作为药物的用途
CN101065360A (zh) Bay43－9006甲苯磺酸盐的热力学稳定形式
RU2195452C2 (ru) Цианогуанидины, способы их получения и фармацевтический препарат на их основе
CN1314890A (zh) 用作细胞增殖抑制剂的氰基胍化合物
CN1121389C (zh) 细胞增生抑制剂氰基胍
CN1044241C (zh) 氧代吡啶基喹喔啉衍生物及含有它们的药物组合物
RU2195451C2 (ru) Цианогуанидины, способы их получения и фармацевтический препарат на их основе
CN1380288A (zh) 四氢异喹啉羟肟酸磺酰胺类化合物、合成方法及其用途
HK1027562B (en) Cyanoguanidines as cell proliferation inhibitors
CN1258280A (zh) 用作细胞增生抑制剂的氰基酰胺类
CN1296489A (zh) 膦酸二酯衍生物
CN1049497A (zh) 取代的苯甲酰脲化合物或它们的盐、它们的制备方法及含有该类物质的抗肿瘤组合物
HK1027572A (en) Cyanoguanidines as cell proliferation inhibitors
HK1027351A (en) Cyanoamidines as cell proliferation inhibitors
CZ419199A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace
HK1066216A1 (en) Novel pyridyl cyanoguanidine compounds
CN1223256A (zh) 用作抗转移药的具有生物活性的脲基衍生物
CZ9904237A3 (cs) Kyanoguanidiny jako inhibitory buněčné proliferace
HK1066216B (en) Novel pyridyl cyanoguanidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20030730

CX01 Expiry of patent term